Divis Laboratories Ltd's Q4FY25 Quarter Results
- 18 May 2025
Result Summary
- Divis Laboratories Ltd reported a 0.8% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 18.1%.
- Its expenses for the quarter were down by 0.4% QoQ and up 7.6% YoY.
- The net profit decreased 8.7% QoQ and increased 67.6% YoY.
- The earnings per share (EPS) of Divis Laboratories Ltd stood at 20.3 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 2382.00 | 2401.00 | 2016.92 | -0.8% | 18.1% |
Total Expenses | 1669.00 | 1675.00 | 1550.44 | -0.4% | 7.6% |
Profit Before Tax | 713.00 | 726.00 | 466.48 | -1.8% | 52.8% |
Tax | 175.00 | 137.00 | 145.51 | 27.7% | 20.3% |
Profit After Tax | 538.00 | 589.00 | 320.97 | -8.7% | 67.6% |
Earnings Per Share | 20.30 | 22.20 | 12.10 | -8.6% | 67.8% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Divis Laboratories Ltd is a prominent pharmaceutical company based in India. The company is known for its focus on manufacturing active pharmaceutical ingredients (APIs) and intermediates, which are essential components in the production of generic drugs. Divis Laboratories serves a global clientele, providing high-quality pharmaceutical products that are integral to the healthcare and pharmaceutical industries. The company has established a strong reputation for its commitment to research and development, which drives innovation and excellence in its product offerings. As of the latest available data, there are no specific updates on recent major developments for Divis Laboratories Ltd.
Revenue
In the fourth quarter of the fiscal year 2025 (Q4FY25), Divis Laboratories Ltd reported a total income of ₹2,382.00 crores. This represents a slight decrease of 0.8% compared to the previous quarter (Q3FY25), where the total income was ₹2,401.00 crores. However, compared to the same quarter in the previous fiscal year (Q4FY24), where the total income was ₹2,016.92 crores, there is a significant year-over-year increase of 18.1%. This growth highlights the company's ability to enhance its revenue generation over the span of a year, despite a minor quarter-over-quarter decline.
Profitability
The company reported a profit before tax of ₹713.00 crores in Q4FY25, reflecting a decrease of 1.8% from ₹726.00 crores in Q3FY25. However, on a year-over-year basis, this figure marks a substantial increase of 52.8% from ₹466.48 crores in Q4FY24. Following the deduction of taxes, the profit after tax for Q4FY25 stood at ₹538.00 crores, which declined by 8.7% from ₹589.00 crores in the previous quarter. Nevertheless, there is a notable year-over-year increase of 67.6% from ₹320.97 crores. The earnings per share (EPS) for Q4FY25 was ₹20.30, reflecting a decrease of 8.6% from ₹22.20 in Q3FY25, but a significant increase of 67.8% from ₹12.10 in Q4FY24.
Operating Metrics
The total expenses for Divis Laboratories Ltd in Q4FY25 amounted to ₹1,669.00 crores, showing a slight decrease of 0.4% from ₹1,675.00 crores in Q3FY25. Compared to Q4FY24, where the expenses were ₹1,550.44 crores, there is a year-over-year increase of 7.6%. The tax expense in Q4FY25 was ₹175.00 crores, which is a 27.7% increase from ₹137.00 crores in Q3FY25, and a 20.3% increase from ₹145.51 crores in Q4FY24. These metrics indicate a consistent increase in tax obligations in both the quarterly and yearly comparisons, reflecting the company's taxable income trends.